Current & Future Trends for Big Data in Pharma

1
Big Data in Pharma Current Future Trends for
Big Data Utilization Across Commercial Function
Best Practices, LLC Strategic Benchmarking
Research Study with Segmented Responses by
Commercial Function www.best-in-class.com
2
Table of Contents

• Executive Summary pp. 3-8
• Research Overview pp. 4
• Universe of Learning pp. 5-6
• Big Data Team Overview and Key Study Insights
  pp. 7-8
• Quantitative Key Findings pp. 9-12
• Defining Big Data pp. 13-20
• Data Types and Sources pp. 21-26
• Data Producers, Dissemination Requestors pp.
  27-31
• Centralization pp.
  32-34
• Governance and Leadership pp. 35-51
• About Best Practices, LLC pp. 52

3
Research Project Objectives Methodology
Best Practices, LLC, conducted a customized
study with responses segmented by medical,
commercial and HEOR functions - to better
understand the growing influence of Big Data in
the biopharmaceutical sector and how it impacts
medical, HEOR, and commercial operations in the
U.S.

• Produce reliable industry metrics on current and
  future trends for Big Data utilization across
  medical, commercial and HEOR groups.

Research Goal
Topics Covered

• Types of Big Data Projects Used to Support
  Medical, Commercial and HEOR Decisions
• Big Data Capabilities and Governance
• Types and Value of Data Used for Big Data
  Projects
• Big Data Staffing and Budget Levels
• Value Rating of Partnerships on Big Data Projects
• Policies and Procedures Governing Big Data
  Activities

• Investigate data types, data partnerships, and
  staffing/budget levels companies are using as
  they move to a more analytically based approach
  to commercial, HEOR medical decisions.

Research Overview

• Best Practices, LLC engaged 12 leaders from 12
  pharmaceutical companies through a benchmarking
  survey.
• Research analysts also conducted seven deep-dive
  executive interviews with selected benchmark
  participants.

Research Methodology
4
Twelve Companies Participated in the Commercial
Segment
12 analytics, marketing and HEOR leaders from 12
different companies participated in this study.
Participants were recruited because of their
presumed investment in Big Data analytics.
Benchmark Class
5
Understanding Big Data Use in Medical, HEOR
Commercial Decision-Making

• Big Data Questions
• Medical
• Commercial
• HEOR

Analytics Team Big Data Function

• Big Data Decisions
• Go/No Clinical Decisions
• ID Market Opportunities
• Developing Economic Models/Assessments

• Big Data Info Types
• Electronic Health Records
• Government Cost Data
• Health Outcomes

• Big Data Projects
• Value Proposition Development
• Post-Launch Performance
• Real World Studies

6
Quantitative Findings

• Across the commercial segment, the following key
  Big Data findings were observed in this study

Only 5 of 36 types of Transactional, Reported,
Online, Scientific and Machine-Generated data
were rated highly valuable by a majority of study
participants. They were Claims EHR (Electronic
Health Records) Health Outcomes (provider/payer
reported) Real World Studies and Registries. No
types of Online or Machine-Generated data were
rated highly valuable by a majority of any
segment. Forty percent of the study participants
said they have a centralized/dedicated Big Data
group. Between 30-40 of participants said
they expect their data capabilities to increase
over the next two years.
Only 5 of 36 Types of Data Rated as Highly
Valuable
Most Have Centralized or Dedicated Big Data Team
or Function
Small Percent of Participants Expect Data
Capabilities to Increase
7
Transactional Data Commercial Rates Claims, EMR
Most Valuable

• While a majority of commercial participants rated
  claims and Electronic Medical Records (EMR) as
  the most valuable types of transactional data for
  Big Data studies, 50 also cited point of sale
  as highly impactful or valuable.

Q How impactful (or valuable) has each of the
following types of transactional data sources
proven to be?
N12
8
Commercial Leaders May Face Barriers to
Centralized Data

• Commercial leaders were least likely to describe
  their analytics as centralized or dedicated. This
  data point may be driven by discomfort with
  analysts who address both marketing and clinical
  questions, something a centralized analytics
  function might try to do.

Q Do you have a centralized/ dedicated group of
individuals to support Big Data projects?
N12
9
Commercial Sees Highest Uncertainty On Dedicated
Role

• Commercial leaders were most likely to not know
  the future structure of their analytics efforts,
  as well as least likely to have
  centralized/dedicated personnel already in place.
  This may be driven by heretofore strict
  separation of clinical and marketing functions.

Q When do you expect your organization will
establish a Big Data team?
N12
10
Capabilities Outstrip Governance for Commercial

• Commercial leaders reported marginally more often
  that there were Big Data capabilities in Asia
  than other functions. The gap between those with
  capabilities and those with governance is most
  pronounced among commercial leaders.

Q Please indicate the regions below where your
organization has Big Data capabilities, and where
Big Data governance resides.
N12
11
About Best Practices, LLC
Best Practices, LLC is a research and consulting
firm that conducts work based on the simple yet
profound principle that organizations can chart a
course to superior economic performance by
studying the best business practices, operating
tactics, and winning strategies of world-class
companies. Best Practices, LLC 6350 Quadrangle
Drive, Suite 200 Chapel Hill, NC
27517 www.best-in-class.com Download Full Report
Download Full Report